942297-64-5Relevant academic research and scientific papers
Protein-protein interface mimicry by an oxazoline piperidine-2,4-dione
Li, Xun,Taechalertpaisarn, Jaru,Xin, Dongyue,Burgess, Kevin
supporting information, p. 632 - 635 (2015/03/05)
Representative minimalist mimics 1 were prepared from amino acids. Scaffold 1 was not designed to mimic any particular secondary structure, but simulated accessible conformations of this material were compared with common ideal secondary structures and with >125000 different protein-protein interaction (PPI) interfaces. This data mining exercise indicates that scaffolds 1 can mimic features of sheet-turn-sheets, somewhat fewer helical motifs, and numerous PPI interface regions that do not resemble any particular secondary structure.
First Cdc7 kinase inhibitors: Pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery
Menichincheri, Maria,Bargiotti, Alberto,Berthelsen, Jens,Bertrand, Jay A.,Bossi, Roberto,Ciavolella, Antonella,Cirla, Alessandra,Cristiani, Cinzia,Croci, Valter,D'Alessio, Roberto,Fasolini, Marina,Fiorentini, Francesco,Forte, Barbara,Isacchi, Antonella,Martina, Katia,Molinari, Antonio,Montagnoli, Alessia,Orsini, Paolo,Orzi, Fabrizio,Pesenti, Enrico,Pezzetta, Daniele,Pillan, Antonio,Poggesi, Italo,Roletto, Fulvia,Scolaro, Alessandra,Tato, Marco,Tibolla, Marcellino,Valsasina, Barbara,Varasi, Mario,Volpi, Daniele,Santocanale, Corrado,Vanotti, Ermes
body text, p. 293 - 307 (2009/10/09)
Cdc7 kinase is a key regulator of the S-phase of the cell cycle, known to promote the activation of DNA replication origins in eukaryotic organisms. Cdc7 inhibition can cause tumor-cell death in a p53-independent manner, supporting the rationale for devel
Heteroarylpyrrolopyridinones active as kinase inhibitors
-
Page/Page column 19, (2008/06/13)
Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5 and R6 are as defined in the specification or a pharmaceutically acceptable salt or solvate thereof, compositions thereof,
